医薬品市場規模・シェア・動向分析レポート：分子タイプ別、製品別、タイプ別、疾患別、剤形別、年齢層別、投与経路別、エンドマーケット別、地域別、セグメント動向：2023年～2030年

医薬品市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の医薬品市場規模は2023年から2030年にかけてCAGR 6.12%で拡大し、2030年には2兆3,632億5,000万米ドルに達する見込みです。

医薬品市場の成長は、慢性疾患の蔓延が増加し、新規治療薬の開発ニーズが高まっていることに起因しています。National Council on Agingによると、高齢者人口の約95％が少なくとも1つの慢性疾患を抱えており、約80％が2つ以上の慢性疾患を抱えていると推定されています。さらに、糖尿病、関節炎、心臓病などの慢性疾患は、高齢者人口に不釣り合いに影響を及ぼしています。

予防、早期発見、重点的な治療、効果的な治療のためには、意識が重要です。病気やその症状を自覚している人は、検診や検査、健康診断といった予防措置を取る傾向が強いです。様々な病気に対する意識の高まりも、医薬品分野を牽引する要素です。がんや糖尿病といった病気について人々が認識するようになったことで、それらの病気を発症した場合に治療を受ける可能性が高まっています。公的機関や民間団体により、国民に意識を広め、教育するためのさまざまな取り組みが行われています。さらに、多くの人々が処方薬費用をカバーする保険に加入するようになり、医薬品需要の増加に寄与しています。

さらに、新規治療薬の開発における技術の進歩により、医薬品需要は世界的に大幅に増加しています。製薬業界は、研究開発だけでなく、製品の販売や流通にもかつてない勢いで投資しています。この業界は、人々の健康に明確かつ直接的に取り組むことに重点を置いています。製薬産業は患者のケアと地域社会の発展に不可欠であり、数多くの救命治療を提供し、雇用を生み出し、世界経済に貢献しています。

ワクチン製造、発酵プロセス、バイオテクノロジーには、細菌やウイルスなど多くの生物学的製剤が使用されています。同市場は、巨大製薬会社、中堅特殊製薬会社、バーチャル製薬会社、ジェネリックメーカー、小規模バイオテクノロジー・バイオ医薬品企業など、多様な企業で構成されています。さらに、さまざまな治療用製剤の開発・製剤化に携わる主なプレーヤーは、新規医薬品の開発と市場競争力の維持のため、共同研究や提携に注力しています。

さらに、症状の予防と治療に対する需要の高まりに対応するため、複数の企業が新規医薬品の開発に取り組んでいます。例えば、2023年4月、F.ホフマン・ラ・ロシュ社は、2022年1月にFDAの承認を取得した同社の湿性加齢黄斑変性症治療薬Vabysmoが、2023年第1四半期に約5億米ドルの売上をもたらしたと発表しました。同剤の売上は前年同期比500％以上増加し、多発性硬化症治療薬オクレバスや血友病治療薬ヘムリブラなどの競合薬を上回った。さらに、ノバルティスAGは2023年7月、レクビオ（一般名：インクリシラン）について、心臓疾患のリスクが高いLDL-C高値患者の治療薬としての適応拡大承認を米国FDAから取得しました。

医薬品市場レポートハイライト

• 分子タイプ別では、従来型医薬品（低分子）が市場全体を支配。医薬品市場における従来型医薬品の優位性は、確立された製造プロセス、予測可能な薬物動態、経口バイオアベイラビリティによるものです。
• 製品別では、ブランド医薬品が2022年の医薬品市場で最大の売上高シェアを占めたが、これはブランド医薬品を専門とする巨大な製薬企業が古くから市場に存在しているためです。
• タイプ別では、OTC医薬品が予測期間中に最も速い成長率を示すと予想されるが、これは、医師の診察を受ける必要性が減少したことにより、このチャネルを通じた医薬品の調達が容易になったためです。
• 疾患別では、がんが2022年の医薬品市場を独占しました。同市場におけるがん分野の優位性は、さまざまな種類のがんの世界の罹患率の上昇、革新的かつ効果的な治療法に対する需要の増加、この分野への大規模な投資と研究など、いくつかの主要な要因によるものと考えられます。
• 剤形別では、錠剤が2022年の医薬品市場で最大の売上シェアを占めました。
• 投与経路では、経口投与セグメントが2022年の世界市場を独占しました。
• 年齢層別では、様々な医薬品を消費する患者プールにおいて世界的に成人人口が優位を占めていることから、成人セグメントが予測期間中に最も速い成長を示すと予想されます。
• 最終市場に関しては、高齢化、慢性疾患の増加、治療法の進歩によるヘルスケア需要の高まりから、病院が医薬品業界を支配しています。
• 北米は2022年に最大の売上シェアを占めたが、これは地域のヘルスケアインフラが発達していること、慢性疾患の症例が増加していること、複数の主要プレーヤーが存在すること、適切で革新的な医薬品が入手可能であることなどに起因しています。

目次

第1章 医薬品市場：調査手法と範囲

第2章 医薬品市場：エグゼクティブサマリー

• 市場スナップショット
• セグメントのスナップショット
• 競合情勢のスナップショット

第3章 医薬品市場の変数、動向、および範囲

• 市場セグメンテーションと範囲
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ポーターのファイブフォース分析
• PESTLE分析

第4章 医薬品市場：分子タイプの見通し推定・動向分析

• 分子タイプの見通し：変動分析
• 生物製剤およびバイオシミラー（高分子）
  • 生物製剤およびバイオシミラー市場推計・予測、2018年～2030年
• 従来型医薬品（低分子）
  • 従来型医薬品市場推計・予測、2018年～2030年

第5章 医薬品市場：製品推定・動向分析

• 医薬品市場：製品変動分析
• ブランド
  • ブランド製品市場収益推計と予測、2018年～2030年
• ジェネリック
  • ジェネリック製品市場収益推計と予測、2018年～2030年

第6章 医薬品市場：タイプの推定・動向分析

• 医薬品市場：タイプの変動分析
• 処方箋
  • 処方箋市場収益推計と予測、2018年～2030年
• OTC
  • OTC市場収益推計と予測、2018年～2030年

第7章 医薬品市場：疾患の見通し推定・動向分析

• 医薬品市場：疾患見通しの変動分析
• 心血管疾患
  • 心血管疾患市場収益推計と予測、2018年～2030年
• がん
  • がん市場収益推計と予測、2018年～2030年
• 糖尿病
  • 糖尿病市場収益推計と予測、2018年～2030年
• 感染症
  • 感染症市場収益推計と予測、2018年～2030年
• 神経学的障害
  • 神経疾患市場収益推計と予測、2018年～2030年
• 呼吸器疾患
  • 呼吸器疾患市場収益推計と予測、2018年～2030年
• 自己免疫疾患
  • 自己免疫疾患市場収益推計と予測、2018年～2030年
• 精神的健康障害
  • 精神的健康障害市場収益推計と予測、2018年～2030年
• 胃腸障害
  • 胃腸障害市場収益推計と予測、2018年～2030年
• 女性の健康病気
  • 女性の健康疾患市場収益推計と予測、2018年～2030年
• 遺伝性疾患および希少遺伝性疾患
  • 遺伝性疾患および希少遺伝性疾患市場収益推計および予測、2018年～2030年
• 皮膚疾患
  • 皮膚疾患市場収益推計と予測、2018年～2030年
• 肥満
  • 肥満市場収益推計と予測、2018年～2030年
• 腎疾患
  • 腎疾患市場収益推計と予測、2018年～2030年
• 肝臓病
  • 肝臓病市場収益推計と予測、2018年～2030年
• 血液疾患
  • 血液疾患市場収益推計と予測、2018年～2030年
• 目の状態
  • 目の状態市場収益推計と予測、2018年～2030年
• 不妊症
  • 不妊症市場収益推計と予測、2018年～2030年
• 内分泌疾患
  • 内分泌疾患市場収益推計と予測、2018年～2030年
• アレルギー
  • アレルギー市場収益推計と予測、2018年～2030年
• その他
  • その他の市場収益推計と予測、2018年～2030年

第8章 医薬品市場：投与経路の推定・動向分析

• 医薬品市場：投与経路変動分析
• 経口
  • 経口市場収益推計と予測、2018年～2030年
• 局所
  • 局所市場収益推計と2018年～2030年
• 非経口
  • 非経口市場収益推計と予測、2018年～2030年
• 吸入
  • 吸入市場収益推計と予測、2018年～2030年
• その他
  • その他市場収益推計と予測、2018年～2030年

第9章 医薬品市場：剤形の推定・動向分析

• 医薬品市場：剤形変動分析
• タブレット
  • タブレット市場収益推計と予測、2018年～2030年
• カプセル
  • カプセル市場収益推計と2018年～2030年
• 注射
  • 注射市場収益推計と予測、2018年～2030年
• スプレー
  • スプレー市場収益推計と予測、2018年～2030年
• サスペンション
  • サスペンション市場収益推計と予測、2018年～2030年
• 粉末
  • 粉末市場収益推計と予測、2018年～2030年
• その他の処方
  • その他の製剤市場収益推計と予測、2018年～2030年

第10章 医薬品市場：年齢層の推定・動向分析

• 医薬品市場：年齢層の変動分析
• 子供・青少年
  • 子供・青少年市場収益推計と予測、2018年～2030年
• 成人
  • 成人市場収益推計と予測、2018年～2030年
• 高齢者
  • 高齢者市場収益推計と予測、2018年～2030年

第11章 医薬品市場：最終市場推定・動向分析

• 医薬品市場：最終市場変動分析
• 病院
  • 病院市場収益推計と予測、2018年～2030年
• クリニック
  • クリニック市場収益推計と予測、2018年～2030年
• その他
  • その他の市場収益推計と予測、2018年～2030年

第12章 医薬品市場：地域ビジネス分析

• 地域別医薬品市場シェア、2022年および2030年
• 北米
  • 北米の医薬品市場、2018年～2030年
  • 米国
  • カナダ
• 欧州
  • 欧州の医薬品市場、2018年～2030年
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • アジア太平洋の医薬品市場、2018年～2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ラテンアメリカの医薬品市場、2018年～2030年
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカの医薬品市場、2018年～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第13章 競合情勢

• 企業の分類
• 戦略マッピング
  • 新製品の発売
  • パートナーシップ
  • 取得
  • コラボレーション
  • 資金調達
• 主要企業の市場シェア分析、2022年
• 企業ヒートマップ分析
• 企業プロファイル
  • F. HOFFMANN-LA ROCHE LTD.
  • NOVARTIS AG
  • ABBVIE INC.
  • JOHNSON &JOHNSON SERVICES, INC.
  • MERCK &CO., INC.
  • PFIZER INC.
  • BRISTOL-MYERS SQUIBB COMPANY
  • SANOFI
  • GSK PLC
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 4 Global Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 5 Global Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 6 Global Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 7 Global Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 8 Global Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 9 Global Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 10 Global Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 11 North America Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
• Table 12 North America Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 13 North America Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 14 North America Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 15 North America Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 16 North America Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 17 North America Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 18 North America Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 19 North America Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 20 U.S. Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 21 U.S. Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 22 U.S. Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 23 U.S. Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 24 U.S. Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 25 U.S. Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 26 U.S. Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 27 U.S. Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 28 Canada Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 29 Canada Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 30 Canada Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 31 Canada Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 32 Canada Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 33 Canada Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 34 Canada Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 35 Canada Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 36 Europe Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
• Table 37 Europe Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 38 Europe Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 39 Europe Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 40 Europe Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 41 Europe Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 42 Europe Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 43 Europe Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 44 Europe Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 45 UK Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 46 UK Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 47 UK Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 48 UK Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 49 UK Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 50 UK Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 51 UK Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 52 UK Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 53 Germany Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 54 Germany Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 55 Germany Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 56 Germany Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 57 Germany Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 58 Germany Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 59 Germany Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 60 Germany Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 61 France Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 62 France Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 63 France Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 64 France Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 65 France Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 66 France Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 67 France Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 68 France Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 69 Italy Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 70 Italy Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 71 Italy Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 72 Italy Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 73 Italy Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 74 Italy Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 75 Italy Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 76 Italy Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 77 Spain Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 78 Spain Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 79 Spain Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 80 Spain Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 81 Spain Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 82 Spain Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 83 Spain Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 84 Spain Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 85 Denmark Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 86 Denmark Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 87 Denmark Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 88 Denmark Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 89 Denmark Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 90 Denmark Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 91 Denmark Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 92 Denmark Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 93 Sweden Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 94 Sweden Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 95 Sweden Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 96 Sweden Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 97 Sweden Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 98 Sweden Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 99 Sweden Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 100 Sweden Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 101 Norway Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 102 Norway Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 103 Norway Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 104 Norway Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 105 Norway Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 106 Norway Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 107 Norway Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 108 Norway Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 109 Asia Pacific Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
• Table 110 Asia Pacific Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 111 Asia Pacific Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 112 Asia Pacific Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 113 Asia Pacific Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 114 Asia Pacific Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 115 Asia Pacific Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 116 Asia Pacific Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 117 Asia Pacific Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 118 Japan Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 119 Japan Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 120 Japan Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 121 Japan Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 122 Japan Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 123 Japan Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 124 Japan Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 125 Japan Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 126 China Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 127 China Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 128 China Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 129 China Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 130 China Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 131 China Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 132 China Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 133 China Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 134 India Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 135 India Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 136 India Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 137 India Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 138 India Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 139 India Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 140 India Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 141 India Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 142 South Korea Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 143 South Korea Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 144 South Korea Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 145 South Korea Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 146 South Korea Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 147 South Korea Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 148 South Korea Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 149 South Korea Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 150 Australia Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 151 Australia Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 152 Australia Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 153 Australia Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 154 Australia Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 155 Australia Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 156 Australia Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 157 Australia Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 158 Thailand Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 159 Thailand Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 160 Thailand Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 161 Thailand Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 162 Thailand Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 163 Thailand Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 164 Thailand Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 165 Thailand Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 166 Latin America Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
• Table 167 Latin America Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 168 Latin America Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 169 Latin America Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 170 Latin America Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 171 Latin America Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 172 Latin America Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 173 Latin America Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 174 Latin America Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 175 Brazil Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 176 Brazil Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 177 Brazil Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 178 Brazil Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 179 Brazil Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 180 Brazil Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 181 Brazil Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 182 Brazil Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 183 Mexico Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 184 Mexico Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 185 Mexico Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 186 Mexico Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 187 Mexico Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 188 Mexico Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 189 Mexico Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 190 Mexico Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 191 Argentina Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 192 Argentina Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 193 Argentina Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 194 Argentina Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 195 Argentina Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 196 Argentina Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 197 Argentina Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 198 Argentina Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 199 Middle East & Africa Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
• Table 200 Middle East & Africa Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 201 Middle East & Africa Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 202 Middle East & Africa Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 203 Middle East & Africa Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 204 Middle East & Africa Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 205 Middle East & Africa Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 206 Middle East & Africa Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 207 Middle East & Africa Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 208 Saudi Arabia Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 209 Saudi Arabia Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 210 Saudi Arabia Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 211 Saudi Arabia Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 212 Saudi Arabia Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 213 Saudi Arabia Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 214 Saudi Arabia Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 215 Saudi Arabia Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 216 South Africa Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 217 South Africa Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 218 South Africa Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 219 South Africa Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 220 South Africa Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 221 South Africa Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 222 South Africa Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 223 South Africa Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 224 UAE Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 225 UAE Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 226 UAE Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 227 UAE Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 228 UAE Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 229 UAE Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 230 UAE Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 231 UAE Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
• Table 232 Kuwait Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 233 Kuwait Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 234 Kuwait Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 235 Kuwait Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 236 Kuwait Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 237 Kuwait Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
• Table 238 Kuwait Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 239 Kuwait Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)

List of Figures

• Fig. 1 Market Research Process
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain - Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 Pharmaceutical Market Segmentation
• Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
• Fig. 11 Penetration & Growth Prospect Mapping
• Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 13 Porter's Five Forces Analysis
• Fig. 14 Pharmaceutical market: Molecule type outlook and key takeaways
• Fig. 15 Pharmaceutical market: Molecule type movement analysis & market share 2022 & 2030
• Fig. 16 Biologics & biosimilars (large molecules) market, 2018 - 2030 (USD Billion)
• Fig. 17 Conventional drugs (small molecules) market, 2018 - 2030 (USD Billion)
• Fig. 18 Pharmaceutical market: Product outlook and key takeaways
• Fig. 19 Pharmaceutical market: Product movement analysis & market share 2022 & 2030
• Fig. 20 Branded pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 21 Generics pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 22 Pharmaceutical market: Type outlook and key takeaways
• Fig. 23 Pharmaceutical market: Type movement analysis & market share 2022 & 2030
• Fig. 24 Prescription pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 25 OTC pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 26 Pharmaceutical market: Disease outlook and key takeaways
• Fig. 27 Pharmaceutical market: Disease movement analysis & market share 2022 & 2030
• Fig. 28 Cancer market, 2018 - 2030 (USD Billion)
• Fig. 29 Cardiovascular diseases market, 2018 - 2030 (USD Billion)
• Fig. 30 Diabetes market, 2018 - 2030 (USD Billion)
• Fig. 31 Infectious diseases market, 2018 - 2030 (USD Billion)
• Fig. 32 Neurological disorders market, 2018 - 2030 (USD Billion)
• Fig. 33 Respiratory diseases market, 2018 - 2030 (USD Billion)
• Fig. 34 Autoimmune diseases market, 2018 - 2030 (USD Billion)
• Fig. 35 Mental health disorders market, 2018 - 2030 (USD Billion)
• Fig. 36 Gastrointestinal diseases market, 2018 - 2030 (USD Billion)
• Fig. 37 Women's health diseases market, 2018 - 2030 (USD Billion)
• Fig. 38 Genetic and rare genetic diseases market, 2018 - 2030 (USD Billion)
• Fig. 39 Dermatological conditions market, 2018 - 2030 (USD Billion)
• Fig. 40 Obesity market, 2018 - 2030 (USD Billion)
• Fig. 41 Renal diseases market, 2018 - 2030 (USD Billion)
• Fig. 42 Liver conditions market, 2018 - 2030 (USD Billion)
• Fig. 43 Hemotological disorders market, 2018 - 2030 (USD Billion)
• Fig. 44 Eye conditions market, 2018 - 2030 (USD Billion)
• Fig. 45 Infertility conditions market, 2018 - 2030 (USD Billion)
• Fig. 46 Endocrine disorders market, 2018 - 2030 (USD Billion)
• Fig. 47 Allergies market, 2018 - 2030 (USD Billion)
• Fig. 48 Other diseases market, 2018 - 2030 (USD Billion)
• Fig. 49 Pharmaceutical market: Route of administration outlook and key takeaways
• Fig. 50 Pharmaceutical market: Route of administration movement analysis & market share 2022 & 2030
• Fig. 51 Oral pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 52 Topical pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 53 Parenteral pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 54 Inhalations pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 55 Others pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 56 Pharmaceutical market: Formulation outlook and key takeaways
• Fig. 57 Pharmaceutical market: Formulation movement analysis & market share 2022 & 2030
• Fig. 58 Tablets pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 59 Capsules pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 60 Injectables pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 61 Sprays pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 62 Suspensions pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 63 Powders pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 64 Others formulation pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 65 Pharmaceutical market: Age group outlook and key takeaways
• Fig. 66 Pharmaceutical market: Age group movement analysis & market share 2022 & 2030
• Fig. 67 Children & Adolescents pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 68 Adults pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 69 Geriatric pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 70 Pharmaceutical market: End market outlook and key takeaways
• Fig. 71 Pharmaceutical market: End movement analysis & market share 2022 & 2030
• Fig. 72 Hospitals pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 73 Clinics pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 74 Others pharmaceutical market, 2018 - 2030 (USD Billion
• Fig. 75 Regional Outlook, 2022 & 2030
• Fig. 76 Regional Market Dashboard
• Fig. 77 Regional Market Place: Key Takeaways
• Fig. 78 North America, SWOT Analysis
• Fig. 79 Europe, SWOT Analysis
• Fig. 80 Asia Pacific, SWOT Analysis
• Fig. 81 Latin America, SWOT Analysis
• Fig. 82 MEA, SWOT Analysis
• Fig. 83 North America
• Fig. 84 North America Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 85 U.S. Key Country Dynamics
• Fig. 86 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 87 Canada Key Country Dynamics
• Fig. 88 Canada Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 89 Europe
• Fig. 90 Europe Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 91 UK Key Country Dynamics
• Fig. 92 UK Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 93 Germany Key Country Dynamics
• Fig. 94 Germany Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 95 France Key Country Dynamics
• Fig. 96 France Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 97 Italy Key Country Dynamics
• Fig. 98 Italy Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 99 Spain Key Country Dynamics
• Fig. 100 Spain Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 101 Denmark Key Country Dynamics
• Fig. 102 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 103 Sweden Key Country Dynamics
• Fig. 104 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 105 Norway Key Country Dynamics
• Fig. 106 Norway Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 107 Asia Pacific
• Fig. 108 Asia - Pacific Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 109 Japan Key Country Dynamics
• Fig. 110 Japan Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 111 China Key Country Dynamics
• Fig. 112 China Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 113 India Key Country Dynamics
• Fig. 114 India Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 115 Australia Key Country Dynamics
• Fig. 116 Australia Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 117 Thailand Key Country Dynamics
• Fig. 118 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 119 South Korea Key Country Dynamics
• Fig. 120 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 121 Latin America
• Fig. 122 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 123 Brazil Key Country Dynamics
• Fig. 124 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 125 Mexico Key Country Dynamics
• Fig. 126 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 127 Argentina Key Country Dynamics
• Fig. 128 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 129 MEA
• Fig. 130 MEA Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 131 South Africa Key Country Dynamics
• Fig. 132 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 133 Saudi Arabia Key Country Dynamics
• Fig. 134 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 135 UAE Key Country Dynamics
• Fig. 136 UAE Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 137 Kuwait Key Country Dynamics
• Fig. 138 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 139 Strategy Mapping

Pharmaceutical Market Growth & Trends:

The global pharmaceutical market size is expected to reach USD 2,363.25 billion by 2030, expandingat a CAGR of 6.12% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the pharmaceuticals market is attributable to the increasing prevalence of chronic diseases, leading to a growing need for developing novel therapeutics. According to the National Council on Aging, it is estimated that approximately 95% of the older population has at least one chronic ailment, and around 80% has two or more. Moreover, chronic diseases such as diabetes, arthritis, and heart disease disproportionately affect the elderly population.

Awareness is critical for prevention, early detection, focused therapy, and effective treatment. People aware of an illness and its symptoms are more inclined to take preventative measures, such as screenings, tests, and check-ups. The increased awareness of various diseases is another element driving the pharmaceutical space. As people are now aware of diseases such as cancer and diabetes, they are more likely to seek treatment if they develop those conditions. A number of initiatives are taken by public and private organizations to spread awareness and educate the population. Furthermore, many people now have insurance policies that cover prescription drug expenses, contributing to increased pharmaceutical demand.

Moreover,the demand for pharmaceuticals is significantly increasing globally due to advancements in technology in the development of novel therapeutics. The pharmaceutical industry invests at an unprecedented rate in research and development, as well as product sales and distribution. The industry focuses on distinctly and directly addressing people's health. The pharmaceuticals industry is critical to patient care and community development and provides numerous life-saving treatments, generates employment, and contributes to the world economy.

Many biological agents, such as bacteria and viruses, are used in vaccine manufacturing, fermentation processes, and biotechnology. The market is made up of a diverse spectrum of companies, including giant pharma, mid-sized specialty, virtual pharma, generic manufacturers, and small biotechnology and biopharmaceutical organizations. Furthermore, key players involved in developing and formulating various therapeutic formulations are focusing on collaborations and partnerships to develop novel medications and maintain their competitive position in the market.

Moreover, several players are involved in developing novel pharmaceuticals to meet the rising demand for the prevention and treatment of conditions. For instance, in April 2023 , F. Hoffmann-La Roche Ltd. announced that its wet age-related macular degeneration drug, Vabysmo, which received FDA approval in January 2022 , brought around USD 500 million during the first quarter of 2023. The drug's sales increased by more than 500% year-on-year, beating competitors such as multiple sclerosis treatment Ocrevus and the hemophilia medication Hemlibra. Moreover, in July 2023, Novartis AG received U.S. FDA approval for an expanded indication of Leqvio (inclisiran), in order to include treatment of patients with high LDL-C who are at an increased risk of heart diseases.

Pharmaceutical Market Report Highlights:

• Based on molecule type, conventional drugs (small molecules) dominated the overall market. Conventional drugs' dominance in the pharmaceuticals market is due to their well-established manufacturing processes, predictable pharmacokinetics, and oral bioavailability
• Based on product, the branded segment held the largest revenue share in the pharmaceuticals market in 2022, owing to the presence of several giant pharmaceutical players in the market specializing in branded medication since a long time
• Based on type, OTC pharmaceuticals are expected to showcase the fastest growth rate over the forecast period owing to the ease of procurement of medication through this channel aided by the reduced need to visit a physician
• In terms of disease, cancer dominated the pharmaceuticals market in 2022. The dominance of the cancer segment in the market can be attributed to several key factors such as the rising global incidence of various types of cancer, increased demand for innovative & effective treatments, and significant investments and research in this area
• On the basis of formulation, tablets held the largest revenue share in the pharmaceuticals market in 2022, owing to the ease of administration and greater adoption of this formulation
• In terms of route of administration, the oral route of administration segment dominated the global market in 2022
• Based on age group, the adult segment is expected to show fastest growth over the forecast period, owing to the dominance of the adult population globally in the patient pool that consumes various pharmaceuticals
• In terms of the end market, hospitals dominated the pharmaceuticals industry, underscored by the escalating healthcare demands due to an aging population, increased prevalence of chronic illnesses, and advancements in medical treatments
• North America held the largest revenue share in 2022, which can be attributed to the developed regional healthcare infrastructure, growing cases of chronic diseases, presence of several key players, and availability of proper and innovative medications in the region

Table of Contents

Chapter 1. Pharmaceutical Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Pharmaceutical Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Pharmaceutical Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Increasing healthcare spending by the government
    • 3.2.1.2. Improving affordability driven by rising per capita income
    • 3.2.1.3. Increasing awareness about healthcare among the population
    • 3.2.1.4. Increasing access to innovative and modern medicines
    • 3.2.1.5. Demographic and lifestyle changes leading to rising prevalence of chronic diseases
    • 3.2.1.6. Rising chronic diseases and geriatric population
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. COVID - 19 pandemic
    • 3.2.2.2. Intensification of competition from generic and biosimilar drugs
    • 3.2.2.3. Increasing price - sensitivity of customers for non - reimbursed drugs
    • 3.2.2.4. Increasing barriers to market access and decreasing R&D productivity of pharma companies
• 3.3. Porter's Five Forces Analysis
• 3.4. PESTLE Analysis

Chapter 4. Pharmaceutical Market: Molecule Type Outlook Estimates & Trend Analysis

• 4.1. Molecule Type Outlook: Movement Analysis
• 4.2. Biologics & Biosimilars (Large Molecules)
  • 4.2.1. Biologics & Biosimilars Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 4.2.1.1 Monoclonal Antibodies
    • 4.2.1.2 Monoclonal Antibodies Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 4.2.2.3 Vaccines
    • 4.2.2.4 Vaccines Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 4.2.3.5 Cell & Gene Therapy
    • 4.2.3.6 Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 4.2.4.7 Others
    • 4.2.4.8 Others Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
• 4.3. Conventional Drugs (Small Molecules)
  • 4.3.1. Conventional Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Pharmaceutical Market: Product Estimates & Trend Analysis

• 5.1. Pharmaceutical Market: Product Movement Analysis
• 5.2. Branded
  • 5.2.1. Branded Product Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.3. Generic
  • 5.3.1. Generic Product Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Pharmaceutical Market: Type Estimates & Trend Analysis

• 6.1. Pharmaceutical Market: Type Movement Analysis
• 6.2. Prescription
  • 6.2.1. Prescription Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.3. OTC
  • 6.3.1. OTC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Pharmaceutical Market: Diseases Outlook Estimates & Trend Analysis

• 7.1. Pharmaceutical Market: Diseases Outlook Movement Analysis
• 7.2. Cardiovascular diseases
  • 7.2.1. Cardiovascular Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.3. Cancer
  • 7.3.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.4. Diabetes
  • 7.4.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.5. Infectious diseases
  • 7.5.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.6. Neurological disorders
  • 7.6.1. Neurological Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.7. Respiratory diseases
  • 7.7.1. Respiratory Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.8. Autoimmune diseases
  • 7.8.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.9. Mental health disorders
  • 7.9.1. Mental Health Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.10. Gastrointestinal disorders
  • 7.10.1. Gastrointestinal Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.11. Women's Health Diseases
  • 7.11.1. Women's Health Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.12. Genetic and Rare genetic diseases
  • 7.12.1. Genetic and Rare Genetic Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.13. Dermatological conditions
  • 7.13.1. Dermatological Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.14. Obesity
  • 7.14.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.15. Renal diseases
  • 7.15.1. Renal Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.17. Liver conditions
  • 7.17.1. Liver Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.17. Hematological disorders
  • 7.17.1. Hematological Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.18. Eye conditions
  • 7.18.1. Eye Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.19. Infertility conditions
  • 7.19.1. Infertility Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.20. Endocrine disorders
  • 7.20.1. Endocrine Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.21. Allergies
  • 7.21.1. Allergies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.22. Others
  • 7.22.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Pharmaceutical Market: Route of Administration Estimates & Trend Analysis

• 8.1. Pharmaceutical Market: Route of Administration Movement Analysis
• 8.2. Oral
  • 8.2.1. Oral Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.3. Topical
  • 8.3.1. Topical Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.4. Parenteral
  • 8.4.1. Parenteral Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.1.1. Intravenous
    • 8.4.1.2. Intramuscular
• 8.5. Inhalations
  • 8.5.1. Inhalations Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.6. Other
  • 8.6.1. Other Routes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. Pharmaceutical Market: Formulation Estimates & Trend Analysis

• 9.1. Pharmaceutical Market: Formulation Movement Analysis
• 9.2. Tablets
  • 9.2.1. Tablets Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.3. Capsules
  • 9.3.1. Capsules Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.4. Injectable
  • 9.4.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.5. Sprays
  • 9.5.1. Sprays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.6. Suspensions
  • 9.6.1. Suspensions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.7. Powders
  • 9.7.1. Powders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.8. Other Formulations
  • 9.8.1. Other Formulations Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 10. Pharmaceutical Market: Age Group Estimates & Trend Analysis

• 10.1. Pharmaceutical Market: Age Group Movement Analysis
• 10.2. Children & Adolescents
  • 10.2.1. Children & Adolescents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 10.3. Adults
  • 10.3.1. Adults Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 10.4. Geriatric
  • 10.4.1. Geriatric Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 11. Pharmaceutical Market: End Market Estimates & Trend Analysis

• 11.1. Pharmaceutical Market: End Market Movement Analysis
• 11.2. Hospitals
  • 11.2.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 11.3. Clinics
  • 11.3.1. Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 11.4. Others
  • 11.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 12. Pharmaceutical Market: Regional Business Analysis

• 12.1. Pharmaceutical Market Share By Region, 2022 & 2030
• 12.2. North America
  • 12.2.1. North America Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.2.2. U.S.
    • 12.2.2.1. Key Country Dynamics
    • 12.2.2.2. Target Disease Prevalence
    • 12.2.2.3. Competitive Scenario
    • 12.2.2.4. Regulatory Framework
    • 12.2.2.5. Reimbursement Scenario
    • 12.2.2.6. U.S. Pharmaceutical market, 2018 - 2030 (USD MILLION)
  • 12.2.3. Canada
    • 12.2.3.1. Key Country Dynamics
    • 12.2.3.2. Target Disease Prevalence
    • 12.2.3.3. Competitive Scenario
    • 12.2.3.4. Regulatory Framework
    • 12.2.3.5. Reimbursement Scenario
    • 12.2.3.6. Canada Pharmaceutical market, 2018 - 2030 (USD Million)
• 12.3. Europe
  • 12.3.1. Europe Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.3.2. Germany
    • 12.3.2.1. Key Country Dynamics
    • 12.3.2.2. Target Disease Prevalence
    • 12.3.2.3. Competitive Scenario
    • 12.3.2.4. Regulatory Framework
    • 12.3.2.5. Reimbursement Scenario
    • 12.3.2.6. Germany Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.3.3. UK
    • 12.3.3.1. Key Country Dynamics
    • 12.3.3.2. Target Disease Prevalence
    • 12.3.3.3. Competitive Scenario
    • 12.3.3.4. Regulatory Framework
    • 12.3.3.5. Reimbursement Scenario
    • 12.3.3.6. UK Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.3.4. France
    • 12.3.4.1. Key Country Dynamics
    • 12.3.4.2. Target Disease Prevalence
    • 12.3.4.3. Competitive Scenario
    • 12.3.4.4. Regulatory Framework
    • 12.3.4.5. Reimbursement Scenario
    • 12.3.4.6. France Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.3.5. Italy
    • 12.3.5.1. Key Country Dynamics
    • 12.3.5.2. Target Disease Prevalence
    • 12.3.5.3. Competitive Scenario
    • 12.3.5.4. Regulatory Framework
    • 12.3.5.5. Reimbursement Scenario
    • 12.3.5.6. Italy Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.3.6. Spain
    • 12.3.6.1. Key Country Dynamics
    • 12.3.6.2. Target Disease Prevalence
    • 12.3.6.3. Competitive Scenario
    • 12.3.6.4. Regulatory Framework
    • 12.3.6.5. Reimbursement Scenario
    • 12.3.6.6. Spain Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.3.7. Denmark
    • 12.3.12.1. Key Country Dynamics
    • 12.3.12.2. Target Disease Prevalence
    • 12.3.12.3. Competitive Scenario
    • 12.3.12.4. Regulatory Framework
    • 12.3.12.5. Reimbursement Scenario
    • 12.3.12.6. Denmark Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.3.8. Sweden
    • 12.3.8.1. Key Country Dynamics
    • 12.3.8.2. Target Disease Prevalence
    • 12.3.8.3. Competitive Scenario
    • 12.3.8.4. Regulatory Framework
    • 12.3.8.5. Reimbursement Scenario
    • 12.3.8.6. Sweden Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.3.9. Norway
    • 12.3.9.1. Key Country Dynamics
    • 12.3.9.2. Target Disease Prevalence
    • 12.3.9.3. Competitive Scenario
    • 12.3.9.4. Regulatory Framework
    • 12.3.9.5. Reimbursement Scenario
    • 12.3.9.6. Norway Pharmaceutical market, 2018 - 2030 (USD Million)
• 12.4. Asia Pacific
  • 12.4.1. Asia Pacific Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.4.2. Japan
    • 12.4.2.1. Key Country Dynamics
    • 12.4.2.2. Target Disease Prevalence
    • 12.4.2.3. Competitive Scenario
    • 12.4.2.4. Regulatory Framework
    • 12.4.2.5. Reimbursement Scenario
    • 12.4.2.6. Japan Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.4.3. China
    • 12.4.3.1. Key Country Dynamics
    • 12.4.3.2. Target Disease Prevalence
    • 12.4.3.3. Competitive Scenario
    • 12.4.3.4. Regulatory Framework
    • 12.4.3.5. Reimbursement Scenario
    • 12.4.3.6. China Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.4.4. India
    • 12.4.4.1. Key Country Dynamics
    • 12.4.4.2. Target Disease Prevalence
    • 12.4.4.3. Competitive Scenario
    • 12.4.4.4. Regulatory Framework
    • 12.4.4.5. Reimbursement Scenario
    • 12.4.4.6. India Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.4.5. South Korea
    • 12.4.5.1. Key Country Dynamics
    • 12.4.5.2. Target Disease Prevalence
    • 12.4.5.3. Competitive Scenario
    • 12.4.5.4. Regulatory Framework
    • 12.4.5.5. Reimbursement Scenario
    • 12.4.5.6. South Korea Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.4.6. Australia
    • 12.4.6.1. Key Country Dynamics
    • 12.4.6.2. Target Disease Prevalence
    • 12.4.6.3. Competitive Scenario
    • 12.4.6.4. Regulatory Framework
    • 12.4.6.5. Reimbursement Scenario
    • 12.4.6.6. Australia Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.4.7. Thailand
    • 12.4.7.1. Key Country Dynamics
    • 12.4.7.2. Target Disease Prevalence
    • 12.4.7.3. Competitive Scenario
    • 12.4.7.4. Regulatory Framework
    • 12.4.7.5. Reimbursement Scenario
    • 12.4.7.6. Thailand Pharmaceutical market, 2018 - 2030 (USD Million)
• 12.5. Latin America
  • 12.5.1. Latin America Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.5.2. Brazil
    • 12.5.2.1. Key Country Dynamics
    • 12.5.2.2. Target Disease Prevalence
    • 12.5.2.3. Competitive Scenario
    • 12.5.2.4. Regulatory Framework
    • 12.5.2.5. Reimbursement Scenario
    • 12.5.2.6. Brazil Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.5.3. Mexico
    • 12.5.3.1. Key Country Dynamics
    • 12.5.3.2. Target Disease Prevalence
    • 12.5.3.3. Competitive Scenario
    • 12.5.3.4. Regulatory Framework
    • 12.5.3.5. Reimbursement Scenario
    • 12.5.3.6. Mexico Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.5.4. Argentina
    • 12.5.4.1. Key Country Dynamics
    • 12.5.4.2. Target Disease Prevalence
    • 12.5.4.3. Competitive Scenario
    • 12.5.4.4. Regulatory Framework
    • 12.5.4.5. Reimbursement Scenario
    • 12.5.4.6. Argentina Pharmaceutical market, 2018 - 2030 (USD Million)
• 12.6. MEA
  • 12.6.1. MEA Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.6.2. South Africa
    • 12.6.2.1. Key Country Dynamics
    • 12.6.2.2. Target Disease Prevalence
    • 12.6.2.3. Competitive Scenario
    • 12.6.2.4. Regulatory Framework
    • 12.6.2.5. Reimbursement Scenario
    • 12.6.2.6. South Africa Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.6.3. Saudi Arabia
    • 12.6.3.1. Key Country Dynamics
    • 12.6.3.2. Target Disease Prevalence
    • 12.6.3.3. Competitive Scenario
    • 12.6.3.4. Regulatory Framework
    • 12.6.3.5. Reimbursement Scenario
    • 12.6.3.6. Saudi Arabia Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.6.4. UAE
    • 12.6.4.1. Key Country Dynamics
    • 12.6.4.2. Target Disease Prevalence
    • 12.6.4.3. Competitive Scenario
    • 12.6.4.4. Regulatory Framework
    • 12.6.4.5. Reimbursement Scenario
    • 12.6.4.6. UAE Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.6.5. Kuwait
    • 12.6.5.1. Key Country Dynamics
    • 12.6.5.2. Target Disease Prevalence
    • 12.6.5.3. Competitive Scenario
    • 12.6.5.4. Regulatory Framework
    • 12.6.5.5. Reimbursement Scenario
    • 12.6.5.6. Kuwait Pharmaceutical market, 2018 - 2030 (USD Million)

Chapter 13. Competitive Landscape

• 13.1. Company Categorization
• 13.2. Strategy Mapping
  • 13.2.1. New Product Launch
  • 13.2.2. Partnerships
  • 13.2.3. Acquisition
  • 13.2.4. Collaboration
  • 13.2.5. Funding
• 13.3. Key Company Market Share Analysis, 2022
• 13.4. Company Heat Map Analysis
• 13.5. Company Profiles
  • 13.5.1. F. HOFFMANN - LA ROCHE LTD.
    • 13.5.1.1. Company Overview
    • 13.5.1.2. Financial Performance
    • 13.5.1.3. Product Benchmarking
    • 13.5.1.4. Strategic Initiatives
  • 13.5.2. NOVARTIS AG
    • 13.5.2.1. Company Overview
    • 13.5.2.2. Financial Performance
    • 13.5.2.3. Product Benchmarking
    • 13.5.2.4. Strategic Initiatives
  • 13.5.3. ABBVIE INC.
    • 13.5.3.1. Company Overview
    • 13.5.3.2. Financial Performance
    • 13.5.3.3. Product Benchmarking
    • 13.5.3.4. Strategic Initiatives
  • 13.5.4. JOHNSON & JOHNSON SERVICES, INC.
    • 13.5.4.1. Company Overview
    • 13.5.4.2. Financial Performance
    • 13.5.4.3. Product Benchmarking
    • 13.5.4.13. Strategic Initiatives
  • 13.5.5. MERCK & CO., INC.
    • 13.5.5.1. Company Overview
    • 13.5.5.2. Financial Performance
    • 13.5.5.3. Product Benchmarking
    • 13.5.5.4. Strategic Initiatives
  • 13.5.6. PFIZER INC.
    • 13.5.6.1. Company Overview
    • 13.5.6.2. Financial Performance
    • 13.5.6.3. Product Benchmarking
    • 13.5.6.4. Strategic Initiatives
  • 13.5.7. BRISTOL - MYERS SQUIBB COMPANY
    • 13.5.7.1. Company Overview
    • 13.5.7.2. Financial Performance
    • 13.5.7.3. Product Benchmarking
    • 13.5.7.4. Strategic Initiatives
  • 13.5.8. SANOFI
    • 13.5.8.1. Company Overview
    • 13.5.8.2. Financial Performance
    • 13.5.8.3. Product Benchmarking
    • 13.5.8.4. Strategic Initiatives
  • 13.5.9. GSK PLC
    • 13.5.9.1. Company Overview
    • 13.5.9.2. Financial Performance
    • 13.5.9.3. Product Benchmarking
    • 13.5.9.4. Strategic Initiatives
  • 13.5.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 13.5.10.1. Company Overview
    • 13.5.10.2. Financial Performance
    • 13.5.10.3. Product Benchmarking
    • 13.5.10.4. Strategic Initiatives